Kidney Cancer

Atezolizumab Plus Bevacizumab Does Not Improve OS in Renal Cell Carcinoma

Publish Date January 10, 2022

The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.

Oral Targeted Agents for Metastatic RCC Associated With Higher Risk of Adverse Events

Publish Date January 6, 2022

A retrospective study sought to determine the risk of adverse events with the use of TKIs and mTOR inhibitors for renal cell carcinoma in patients with renal impairment or ESRD.

New Agent for VHL-Associated Kidney Cancer Lauded

Publish Date January 5, 2022

Belzutifan makes von Hippel-Lindau disease more manageable, according to an expert.

COVID-19 Vaccines Deemed Safe for Renal Cell Carcinoma Patients on Immune Checkpoint Inhibitors

Publish Date December 31, 2021

The rate of new or worsening immune-related adverse events was no higher than previously reported.

Cytoreductive Nephrectomy Plus Active Surveillance Benefits Some With Metastatic Renal Cell Carcinoma

Publish Date December 30, 2021

The median cancer-specific survival was 56.5 months.

Managing Adverse Reactions to Lenvatinib-Pembrolizumab

Publish Date December 29, 2021

The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.

Gene Expression Profiling Could Inform Treatment of Non-Clear Cell Renal Cell Carcinoma

Publish Date November 8, 2021

Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.

Predicting Long-Term Survival With Nivolumab Plus Ipilimumab in Advanced Renal Cell Carcinoma

Publish Date November 9, 2021

Patients with smaller target lesions at baseline were more likely to be long-term survivors.

High IC and HU Associated With Better Outcomes in Metastatic Renal Cell Carcinoma

Publish Date December 20, 2021

Iodine concentration and Hounsfield units were associated with treatment response and survival.

ICIs Linked With Higher Risk for Cancer Therapy-Related Cardiac Dysfunction

Publish Date December 20, 2021

In a study presented at AHA 2021, researchers aimed to assess the link between cancer therapy-related cardiac dysfunction and immune checkpoint inhibitors.